MSD Animal Health has published positive clinical data for a new vaccine therapy for myxomatosis and rabbit haemorrhagic disease.
The subcutaneously-administered Nobivac Myxo-RHD was shown to provide high-quality protection against both of these two viral diseases, with vaccinated rabbits remaining healthy and suffering no adverse effects.
Researchers trialled the drug at MSD Animal Health's Milton Keynes research centre, with an editorial published in the peer-reviewed journal Veterinary Record suggesting that the product represents a major step forward in rabbit healthcare.
This is particularly important given that only an estimated 15 percent of rabbits receive regular vaccinations for these two conditions.
David Sutton, global technical director for small animal vaccines at MSD Animal Health, said: "The clinical results with Nobivac Myxo-RHD, as reported in this new publication, demonstrate the excellent efficacy and safety profile of this novel vaccine."
Last month, it was announced that the company's established feline hyperthyroidism treatment Vidalta is to be made available across Europe, following its successful introduction in the UK.See all the latest jobs in Animal Health